Retinal Diseases and Treatments

Moving in bioRxiv, medRxiv, Annals of Internal Medicine, Frontiers in Genetics, Molecular therapy. Nucleic acids and Nature Reviews Genetics.

Moved, week to 23 Oct 2026: 0
Papers in 60 days: 11

Add Retinal Diseases and Treatments as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest

Rebuilt 23 October 2026 at 4:17 pm AEDT

Moved this week

Everything that moved →

Nothing in this topic has moved yet this week.

Latest in Retinal Diseases and Treatments

Newest first · last 60 days

Clinically relevant AAV8-PEX1 gene therapy preserves retinal integrity and function long-term in a murine model of Zellweger spectrum disorder
bioRxiv · 22 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.05.11.723906
Open in JClub
Genetic insights into foveal morphology and its associations with pigmentation and age-related macular degeneration
medRxiv · 12 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
- 3 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.06.27.25330434
Open in JClub
Single-cell spatial transcriptomics of inherited retinal degeneration reveals broad and focal organization of disease responses
bioRxiv · 7 Oct 2026 · Preprint
Single-cell spatial transcriptomics uncovers broad and focal organization of degeneration responses in LCA5 mouse retinas, revealing localized injury and stress patterns.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.28.751688
Open in JClub
A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial
medRxiv · 6 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.19.26363031
Open in JClub
VCP inhibition prevents cone photoreceptor degeneration in the cpfl1 mouse model of achromatopsia
bioRxiv · 26 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.21.753131
Open in JClub
Transducin: an open-source pipeline recovering SNOMED-CT coded measurements from the undocumented Optopol .OPT and Zeiss Cirrus private-tag formats as DICOM Structured Reports
medRxiv · 25 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.07.14.26357256
Open in JClub
rAAV-mediated multi-miRNA delivery targeting MAPK pathway suppresses laser-induced choroidal neovascularization in mice.
Molecular therapy. Nucleic acids · 16 Sept 2026 · Journal Article
rAAV-mediated delivery of multiple miRNAs targeting MAPK signaling suppresses laser-induced choroidal neovascularization in mice by reducing CNV leakage and angiogenesis.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42857105
Open in JClub
Variant-to-gene mapping in ocular cell types identifies candidate effector genes for primary open-angle glaucoma
bioRxiv · 14 Sept 2026 · Preprint
Mapping variants to genes in ocular cells reveals 80 candidate effector genes for primary open-angle glaucoma, highlighting ARHGEF12's role in disease mechanisms.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.02.20.707051
Open in JClub
Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.
Annals of Internal Medicine · 1 Sept 2026 · Observational Study
Glucagon-like peptide-1 receptor agonists increase the 18-month risk of ischemic optic neuropathy by approximately 3 to 3.6 cases per 10,000 patients compared to other diabetes medications.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42441967
Open in JClub
Revisiting retinal and macular degeneration in the genomics era.
Nature Reviews Genetics · 1 Sept 2026 · Review
Genomic advances have identified causal genes and variants, paving the way for targeted therapies for retinal and macular degeneration affecting millions globally.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42230802
Open in JClub
Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration.
Frontiers in Genetics · 1 Sept 2026 · Journal Article
Suprachoroidal delivery of AL-001 achieves sustained aflibercept expression and superior efficacy with minimal inflammation in a nonhuman primate model of wet age-related macular degeneration.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42745920
Open in JClub

Add Retinal Diseases and Treatments as an interest in JClub

Journals this month

All journals →

Topics moving, week to 23 Oct 2026

All topics →

By field

All journals by field →

Moved this week

Latest in Retinal Diseases and Treatments

Browse JClub